By using two-color phenotypic analysis with fluorescein isothiocyanate-anti-CD38 and phycoerythrin-anti-CD19 antibodies, we found that pre-B cells (CD38+CD19+) signifcantly decreased depending on the number of plasma cells (CD38++CD19+) in the bone marrow (BM) in the cases with BM plasmacytosis, such as myelomas and even polyclonal gammopathy. To clarify how plasma cells suppress survival of pre-B cells, we examined the effect of plasma cells on the survival of pre-B cells with or without BM-derived stromal cells in vitro. Pre-B cells alone rapidly entered apoptosis, but interleukin-7 (IL-7). a BM stromal cell line (KM-102). or culture supernatants of KM-102 cells could support pre-B cell survival. On the other hand, inhibitory factors such as transforming growth factor-pl (TGF-p1) and macrophage in- So-called pre-B cells are the early stage B cells, ie, the stage during which clonal diversity of B-cell lineage is established by rearrangement of the IgH chain followed by that of the light chain gene and during which the clonal expansion is also determined in the BM. These pre-B cells continue to proliferate in contact with stromal cells and under interleukin-7 (IL-7) secreted from these stromal cells.' According to cell cloning experiments, these pre-B cell compartments are divided into following three stages: (1) the proliferation of the earliest pre-B cells is dependent on stromal cells and occurs without added IL-7; (2) the intermediate pre-B cells proliferate either on stromal cells or with exogenously added IL-7; and (3) the late pre-B cells survive without stromal cells in the presence of IL-7.3 Therefore, either IL-7 or stromal cells are necesary to support survival of pre-B-cell compartments. On the other hand, the development of the early stage of B cells in the BM can be inhibited by the action of inhibitory cytokines such as transforming growth factor-p1 (TGF-p1)35 macrophage inflammatory protein-la (MIP-la), and MIP-lp.6.7
So-called pre-B cells are the early stage B cells, ie, the stage during which clonal diversity of B-cell lineage is established by rearrangement of the IgH chain followed by that of the light chain gene and during which the clonal expansion is also determined in the BM. These pre-B cells continue to proliferate in contact with stromal cells and under interleukin-7 (IL-7) secreted from these stromal cells.' According to cell cloning experiments, these pre-B cell compartments are divided into following three stages: (1) the proliferation of the earliest pre-B cells is dependent on stromal cells and occurs without added IL-7; (2) the intermediate pre-B cells proliferate either on stromal cells or with exogenously added IL-7; and (3) the late pre-B cells survive without stromal cells in the presence of IL-7.3 Therefore, either IL-7 or stromal cells are necesary to support survival of pre-B-cell compartments. On the other hand, the development of the early stage of B cells in the BM can be inhibited by the action of inhibitory cytokines such as transforming growth factor-p1 (TGF-p1)35 macrophage inflammatory protein-la (MIP-la), and MIP-lp. 6.7 In this report, we first confirmed that pre-B-cell fractions were suppressed in the BM from the patients with MM and marked polyclonal plasmacytosis; plasma cells increased up to more than 10% in the BM mononuclear cells. Second, we investigated whether plasma (myeloma) cells could suppress survival of pre-B cells with or without BM-derived stromal cells in vitro. Finally, to characterize the function of stromal mary BM stromal cells induced apoptosis of pre-B cells. Supernatants of coculture with KM-102 and myeloma cell lines (KMS-5) also could suppress survival of pre-B cells. Furthermore, we examined the expression of IL-7, TGF-p1, and MIPlp mRNA in KM-102 cells and primary stromal cells cocultured with myeloma cell lines (KMS-5). In these cells, IL-7 mRNA was downregulated, but the expression of TGF-p1 and MIP-lp mRNA was augmented. Therefore, these results suggest that BM-derived stromal cells attached t o plasma (myeloma) cells were modulated t o secrete lesser levels of supporting factor (IL-7) and higher levels of inhibitory factors (TGF-PI and MIP-1p) for pre-B cell survival, which could explain why the increased number of plasma (myeloma) cells induced suppression of pre-B cells in the BM. This phenomenon may represent a feedback loop between pre-B cells and plasma cells via BM stromal cells in the BM. 
CD38"CD19'
(or CD19-) fractions on two-color histograms as described previously. ' I The sorted pre-B cells ( 1 X IO' to 1 x IO4) were cultured in 6-well microtiter plates (no.258 10; Coming, Coming, NY) with RPMI-1640 medium supplemented with 10% FCS and 1 x IO' molL 2-mercaptoethanol for 1 to 2 days at 37°C in a 5% C 0 2 humidified atmosphere. In some experiments, a BM-derived stromal cell line, KM-102, was precultured on 6-well microtiter plates 1 or 2 days before experiments, and the sorted pre-B cells and plasma cells (or myeloma cell lines) were seeded on these stromal cell lines. KM-102 cell lines and KMS-5 cell lines were cultured in RPMI-1640 medium supplemented with 10% FCS and 2-mercaptoethanol for 2 or 3 days. In other experiments, pre-B cells in the presence of recombinant IL-7 (rIL-7: IO nglmL; Genzyme, Boston, MA) were cultured with culture supematants of stromal cells (50% vol/vol) or of stromal cells ( 1 x 10' cells) and plasma cells ( 1 x IO5 cells) or with rMIPla (100 ng/mL), rMIP-10 (100 ng/mL). or rTGF-01 (10 ng/mL: Genzyme). After 1 or 2 days culture, the cells were harvested and stained with fluoescein diacetate (FDA; Aldrich Chemical Co, Milwaukee, W1) and popidium iodide (PI; Sigma, St Louis, MO) for estimating cell viability as described previously.'2 Two-color fluorescent analysis of fluorescent FDA (x-axis, log scale) and uptake of PI (y-axis, log scale) were performed by a cell sorter (Epics Elite): viable, apoptotic, and dead cells were FDA'PI-, FDA-PI-, and FDA-PI', respectively. Viable cells were confirmed to be located at region A on forward scatter (FS) and side scatter (SS) histograms.
Reverse transcription-polvmerase chain reaction (RT-PCR) for mRNA expression of various cytokines. KM-102 or primary BM stromal cells (5 X 10' cells) were cultured with or without myeloma cell lines, KMS-5 (2 X IO6 cells), for 1 day and were harvested. The extraction of mRNA was performed by using oligo dT-latex 
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10.
beads (Oligotex-dT30: Takara, Kyoto, Japan). Accordig to standard methods using the random hexamer. reversed cDNA was amplified for 30 cycles with specific primers as follows: 0-actin, 5'-ATCTGGCACCACACCTTCTACAATGAGCTGCG and 3'- 
RESULTS
Suppression of pre-B-cell fractions in BM plasmacytosis. As reported previously," B-lineage cells were clearly distinguished by two-color analysis with PE-anti-CD 19 and FITC-antLCD38 antibodies; mature B cells were CD38-CD19', pre-B cells were CD38'CD19+, and plasma cells were CD38"CD19'.
Pre-B-cell fractions were estimated by the two-color analysis in 25 cases of MM, 5 cases of BMG, and 5 cases of marked polyclonal plasmacytosis such as chronic infection and bacterial sepsis. In healthy donors (n = 5), pre-B-cell fractions were detected at 9.9% 2 2.7% in BM mononuclear cells ( Table 1 . Thus, these data show that suppression of pre-B cells was observed in the cases with markedly increased numbers of plasma cells (either polyclonal or monoclonal) but was not observed in the cases of BMG that had no suppression of residual Ig in the serum.
Pre-B cells are subclassified into two subpopulations, as shown in Fig 2, ie, CD19+CD20-(region F) early pre-B cells (80% to 85% in pre-B-cell fraction) and CD19+ CD20' (region G) late pre-B cells (15% to 20%) by threecolor analysis (Fig 2a) . In myeloma cases (Fig 2b) in which pre-B cells were suppressed, ratios of CD19TD20-(region F) early to CD19+CD20+ (region G) late pre-B cells were almost the same as those in healthy donors (Fig 2a) . These were also the cases of polyclonal marked plasmacytosis (Fig 2c) . Therefore, these results suggest that suppression of pre-B-cell fractions is induced at the stage of early pre-B cells (CD19+CD20-) in marked BM plasmacytosis of myeloma as well as in polyclonal plasmacytosis.
Plasma cells do not affect survival of pre-B cells directly but can suppress it in the presence of BM stromal cell lines. After culture with medium alone or rIL-7 for 2 days, pre-B cells (CD19+CD38+) sorted by a cell sorter, as described in Materials and Methods, were harvested, restained with FITC-anti-CD38 and PE-anti-CD19 antibodies, and analyzed at the region of A on FS/SS histogram as shown in Fig 3. It was confirmed by FDA and PI staining that viable cells (FDA'PI-cells) were located at the region of A on FS/SS histogram (data not shown). Figure 3 shows a representative case in which viable pre-B cells were markedly decreased in number with medium alone (Fig 3b) but could maintain the cell number in the presence of IL-7 after 2 days (Fig 3c) . However, survival of pre-B cells could not be suppressed when cocultured with plasma cells themselves (Fig 3d) . BM stromal cell lines, Kh4-102 cells, could also support the survival of pre-B cells (Fig 3e) . but addition of plasma cells decreased the number of viable pre-B cells in coculture with Kh4-102 cells (Fig 39. Therefore, these data suggest that plasma cells cannot suppress survival of pre-B (Fig 5a) .
Fig 3. Survival of preB cells was not suppressed by plasma cells alone, but by coculture of KM-102 and plasma cells. Pre-B cells and plasma cells from a healthy donor were separated on CD19/CD38 analysis (a) and were sorted by a cell sorter, respectively. PreB cells (1 x 10' cells1 were cultured for 2 days with medium alone lbl, with rlL-7 (10 nglmL; cl, with isolated plasma cells (1 x 10' cells; dl, with KM-102 cells I1 x '10' cells; e), or with KM-102 cells and plasma cells (f). The cells were harvested and stained with FITC-antLCD38 and PE-antLCD19 antibodies, and immunofluorescence was analyzed by a cell sorter (Epics Elite). The total number of viable cells in region E (Pre-BI on CD19/CD38 histograms is as follows
On the other hand, we could not detect either MIP-la or MIP-ID mRNA in KM-102 cells by our RT-PCR when cultured with medium alone (Fig 5b, lane 2) . When KM-102 cells were cultured with KMSJ cells, MIP-10 but not MIP-la mRNA expression was augmented significantly but not markedly in KM-102 cells (Fig 5b, lane 3) . This augmented expression of MIP-I@ and not MIP-la mRNA in KM-102 cells is one of the reasons why supematants of KM-102 plus KMSJ could suppress survival of pre-B cells. Primary BM stromal cells augmented mRNA expression of both MIP-la and MIP-ID markedly when cultured with KMSJ cells as compared with that with BM stromal cells alone (Fig 5b, lanes 5 and 6) .
As shown in Fig 5c, (Fig 5c, lanes 5 and 6) . Therefore, these data suggest that stromal cell lines as well as BM stromal cells were modulated to express IL-7, MIP- considered to proliferate either on IL-7-producing stromal cells or with exogenously added IL-7,? we could explain why pre-B-cell compartments were suppressed by stromal cells attached to increased numbers of plasma (myeloma) cells in the BM. However, it should be noted that suppression of only pre-B-cell compartments cannot give us enough explanation for the suppression of serum residual Ig and impaired synthesis of normal Ig in MM. Other possibilities for the cause of this suppression have already been presented as follows: ( I ) the influence of inhibitory chalones that suppress polyclonal B-cell proliferation or differentiation"; (2) the presence of humoral immunosuppressive substances produced by malignant plasma celIsl6; and (3) the abnormality of host immunoregulatory cells (monocytes and T cell^).'^^'^ Another interesting finding in this report is that suppression of pre-B cells was found even in the cases of polyclonal plasmacytosis with the increased numbers of normal plasma cells. This means that modulation of BM stromal cells is induced by normal plasma cells as well as malignant plasma cells (myeloma cells), and induction of pre-B-cell suppression is not specific to MM but can occur in reactive plasmacytosis in vivo.
In this report, we show that BM stromal cells and cell lines can be modulated to express mRNA of cytokines responsible for pre-B-cell survival when plasma (myeloma) cells attach to these stromal cells. Stimulatory IL-7 mRNA expression is suppressed, but inhibitory MIP-Io and TGFgl mRNA expressions are augmented in these stromal cells.
Nowadays, the regulatory mechanism of cytokine genes such as IL-7, MIP-Io, and TGF-PI has been well investigated but still is not clear. Activator protein-I (AP-I) binding sites, conserved lymphokine element, and SV40 early promoter binding factor (Sp-I) binding sites were detected in 5' regulatory regions of these cytokine genes.'"."' It remains to be clarified why expression of IL-7 mRNA is suppressed and that of MIP-Io and TGF-PI is inversely augmented: ie. how such diverse effects are induced by interaction between stromal cells and plasma (myeloma) cells and which adhesion molecules are involved in such signal transductions. Recently, focal adhesion kinase is reported to be involved in integrin signaling," but the exact mechanism is still under investigation.
Recently, plasma (myeloma) cells in the BM could be subclassified into immature, intermediate, and mature plasma Finally, we here show that plasma cells (myeloma cells) can modulate function of BM stromal cells to suppress the survival of pre-B cells. Further investigation of the exact mechanism will contribute to the understanding of functional redundancy of BM stromal cells in hematopoietic malignancy as well as MM.
